3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Myelodysplastic Syndromes
5
Hodgkin Disease
5
Leukemia, Biphenotypic, Acute
4
Hematologic Neoplasms
4
Leukemia, Myelomonocytic, Chronic
3
Anemia, Refractory, with Excess of Blasts
3
Sarcoma
2
Rhabdomyosarcoma
2
Neuroblastoma
2
Multiple Myeloma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Glioblastoma
2
Burkitt Lymphoma
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Teratoma
1
Solid Tumors
1
Sarcoma, Ewing
1
Rhabdoid Tumor
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Interventions
Specimen Handling
1
Imatinib Mesylate
1
Granulocyte Colony-Stimulating Factor
1
Genetic Counseling
1
Filgrastim
1
Decitabine
1
Clinical Trials, Phase I as Topic
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Congenital Bone Marrow Failure Syndromes
×
Filgrastim
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled